When Treatment Becomes Stress: Iron Redox Dysregulation and Therapeutic Polarity in Long COVID and ME/CFS

A CYNAERA framework for explaining why the same intervention may help, harm, or destabilize depending on metabolic terrain, ferritin signaling, and adaptive reserve.

This paper is part of the CYNAERA Long COVID Library, a growing resource, impacting how infection associated chronic conditions are researched, diagnosed, treated and understood.

By: Cynthia Adinig

Executive Summary

Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and related infection associated chronic conditions (IACCs) are increasingly recognized as disorders involving impaired recovery physiology, fluctuating adaptive reserve, neurovascular instability, autonomic dysfunction, mitochondrial impairment, oxidative stress, and post exertional symptom amplification (Institute of Medicine, 2015; Komaroff and Lipkin, 2021; Davis et al., 2023). Despite growing recognition of these conditions, treatment outcomes remain highly inconsistent. Interventions that improve symptoms in some patients may worsen symptoms in others, while therapies initially tolerated may later trigger destabilization, cognitive collapse, autonomic worsening, or prolonged post exertional malaise (PEM) (Nijs et al., 2013; Davenport et al., 2019).

This paper introduces Therapeutic Polarity™, a CYNAERA systems framework proposing that therapeutic response in IACCs is state dependent rather than universally fixed. Under this model, treatment outcome depends not solely upon the intervention itself, but upon the biologic terrain into which the intervention is introduced. Factors including mitochondrial reserve, endothelial stability, neurovascular compensation, inflammatory burden, oxidative stress, autonomic regulation, iron redox balance, and PEM threshold sensitivity may collectively determine whether a therapy functions as restorative support or destabilizing physiologic stress (Sterling and Eyer, 1988; McEwen, 1998; Naviaux, 2019).

The framework integrates emerging evidence across multiple biologic domains including ferritin and iron dysregulation, ferritin light chain 1 (FTL1) mediated synaptic dysfunction, mitochondrial ATP suppression, cerebral perfusion abnormalities, endothelial dysfunction, autonomic instability, excitation inhibition imbalance, neuroimmune activation, and post exertional physiologic collapse. Recent findings demonstrating that elevated neuronal FTL1 impairs synaptic plasticity, mitochondrial ATP production, and cognitive performance while remaining partially reversible through metabolic support interventions provide a potentially important mechanistic bridge between iron dysregulation, neuro metabolic instability, and cognitive dysfunction . While current FTL1 findings remain largely preclinical, they provide a biologically plausible framework that warrants direct investigation in human IACC populations.

Similarly, accumulating evidence in Long COVID and ME/CFS demonstrates altered cerebral blood flow, endothelial dysfunction, elevated cerebrospinal fluid lactate, impaired neurovascular coupling, oxidative stress accumulation, autonomic dysregulation, and reduced mitochondrial efficiency (Van Campen et al., 2020; Wirth and Scheibenbogen, 2021; Systrom et al., 2022; Appelman et al., 2024) . Collectively, these findings support the possibility that many patients operate within narrowed adaptive reserve states in which physiologic demand may exceed available compensatory capacity.

Within this framework, PEM is interpreted not as generalized fatigue, but as a delayed systems level collapse response occurring when cumulative physiologic demand exceeds available adaptive reserve. Importantly, therapeutic interventions themselves may function as physiologic load events. Exercise rehabilitation, hyperbaric oxygen, stimulants, antivirals, mitochondrial agents, cognitive rehabilitation, and iron related therapies may therefore produce sharply divergent outcomes depending upon current terrain stability, oxidative reserve, endothelial integrity, autonomic compensation, and neurovascular resilience.

The paper additionally proposes that digital biomarker systems and gaming based neurocognitive monitoring may offer sensitive methods for detecting early terrain destabilization before overt functional collapse becomes clinically apparent. Reaction time drift, endurance decline, sensory disengagement, cognitive variability, task abandonment patterns, and delayed recovery signatures may provide measurable indicators of fluctuating reserve states and treatment tolerance (Insel, 2017; Dagum, 2018; Rutkove et al., 2020). Such approaches may improve longitudinal monitoring of cognitive PEM, neurovascular instability, and therapeutic destabilization in both clinical and research settings.

Therapeutic Polarity further suggests that many failed or inconsistent clinical trial outcomes in Long COVID and ME/CFS may partially reflect terrain mismatch rather than complete absence of therapeutic efficacy. Under this interpretation, heterogeneous reserve states, differing PEM thresholds, autonomic instability, oxidative burden, endothelial dysfunction, and neurovascular variability may obscure subgroup specific benefit while increasing treatment induced destabilization (Collins and Varmus, 2015; Ashley, 2016). Importantly, the framework does not propose that treatments are inherently beneficial or harmful. Rather, it proposes that therapeutic efficacy and tolerability may depend heavily upon timing, sequencing, physiologic reserve, and terrain stability.

Accordingly, this paper proposes a broader terrain based model of chronic disease medicine in which treatment efficacy depends upon dynamic biologic context rather than static diagnosis alone. Future precision medicine strategies in Long COVID, ME/CFS, and broader IACCs may therefore require longitudinal reserve monitoring, adaptive treatment sequencing, neurovascular profiling, PEM threshold mapping, digital biomarker integration, and physiologic stratification approaches capable of accounting for fluctuating adaptive stability over time.

Under Therapeutic Polarity, variability itself becomes biologically meaningful. Chronic illness may not simply reflect damaged physiology, but unstable adaptive physiology operating within narrowed reserve margins where treatment outcome depends upon timing, reserve state, sequencing, and terrain integrity.

1. The Help Hurt Paradox in Infection Associated Chronic Conditions

Patients with Long COVID, ME/CFS, dysautonomia, mast cell activation syndrome, chronic Lyme disease, mold associated illness, and related infection associated chronic conditions frequently describe a destabilizing phenomenon in which the same intervention may improve symptoms temporarily before triggering cognitive collapse, autonomic instability, inflammatory worsening, post exertional malaise, or multisystem flare. This pattern appears repeatedly across exercise rehabilitation, oxygen therapies, stimulant medications, mitochondrial supplements, antivirals, autonomic therapies, iron supplementation, cognitive rehabilitation, and immune modulation strategies. Conventional biomedical frameworks often interpret these responses as inconsistency, psychosomatic amplification, treatment intolerance, or unrelated disease variability. However, the reproducibility of these reports across conditions, patient populations, and therapeutic categories suggests a broader systems level phenomenon requiring mechanistic investigation.

In Long COVID and ME/CFS specifically, cognitive impairment often fluctuates according to physiologic demand rather than remaining fixed. Patients may temporarily tolerate stimulation, exertion, oxygen therapy, or enhanced metabolic activity before experiencing delayed deterioration characterized by worsened executive dysfunction, reduced information processing speed, autonomic dysregulation, sensory intolerance, and post exertional symptom amplification (Nakatomi et al., 2014; Komaroff and Lipkin, 2021). Emerging neuroimaging and neurovascular evidence suggests that these states are associated with dynamic alterations in cerebral blood flow, glial activation, metabolic stress, and synaptic regulation rather than classical neurodegenerative injury .

The present framework introduces the concept of Therapeutic Polarity™ to describe this phenomenon. Therapeutic Polarity™ refers to the state dependent shift by which the same intervention may function as therapeutic support in one physiologic context while acting as destabilizing stress in another. Under this model, treatment response is not viewed as fixed or universally predictable. Instead, intervention outcomes are interpreted through the interaction between the therapy and the patient’s current metabolic terrain, inflammatory load, autonomic reserve, mitochondrial capacity, neurovascular state, and post exertional malaise threshold.

This perspective aligns with growing evidence that ME/CFS and Long COVID involve persistent but potentially modifiable neuroimmune and neurometabolic dysregulation rather than irreversible structural degeneration . Neurovascular dysfunction, altered excitation inhibition balance, astrocytic stress, mitochondrial impairment, microglial activation, endothelial dysfunction, and impaired oxygen utilization have all been implicated in cognitive dysfunction and exertional intolerance in these conditions (Wirth and Scheibenbogen, 2021; VanElzakker et al., 2019; Systrom et al., 2022).

Importantly, this model does not propose that treatments such as exercise, oxygen therapy, stimulants, antivirals, or mitochondrial agents are inherently beneficial or harmful. Rather, it proposes that therapeutic effect is conditional upon biologic state. A patient operating within a narrow adaptive metabolic window may experience a treatment not as restorative support but as an additional energetic, oxidative, autonomic, or inflammatory load.

Therapeutic Polarity™ Model

Intervention	Stable Terrain State	Unstable Terrain State
Exercise	Improved conditioning and circulation	Post exertional malaise and inflammatory amplification
Hyperbaric oxygen	Improved cognition and energy	Oxidative stress and autonomic destabilization
Stimulants	Enhanced executive function	Cognitive crash and sympathetic overload
Iron supplementation	Improved oxygen carrying capacity	Oxidative injury and inflammatory stress
Antivirals	Reduced viral burden	Immune destabilization and flare activation

The significance of Therapeutic Polarity™ extends beyond symptom explanation. It provides a possible systems level explanation for treatment inconsistency across IACCs, failed rehabilitation paradigms, high clinical trial dropout rates, and the reproducibility challenges that continue to limit therapeutic advancement in post infectious chronic disease.

2. Post Exertional Malaise as the Governing Failure State

Post exertional malaise represents one of the most defining and disabling features of ME/CFS and Long COVID. Unlike conventional fatigue, post exertional malaise reflects a delayed and disproportionate physiologic deterioration following physical, cognitive, emotional, sensory, or autonomic exertion (Institute of Medicine, 2015). Symptom worsening may occur immediately or emerge hours to days after activity and can persist for prolonged periods, often involving cognitive impairment, orthostatic dysfunction, pain amplification, sensory hypersensitivity, immune activation, and reduced functional capacity.

Traditional models frequently conceptualize exertion as primarily physical. However, accumulating evidence suggests that cognitive processing, sensory stimulation, emotional stress, environmental exposure, and sustained attentional demand may produce comparable physiologic consequences in vulnerable patients (Jason et al., 2011; Davenport et al., 2019). Neuroimaging studies demonstrate altered cerebral blood flow responses and impaired neural recruitment during cognitive challenge in ME/CFS patients, supporting the concept that cognitive exertion itself represents a biologically meaningful metabolic load .

The CYNAERA PEM framework proposes that post exertional malaise functions as a cumulative systems failure response rather than isolated fatigue. Under this model, multiple load domains interact simultaneously across autonomic, immune, vascular, mitochondrial, inflammatory, sensory, endocrine, and neurocognitive systems. A patient may therefore tolerate a given intervention during one physiologic state while experiencing collapse during another state where cumulative reserve has already been depleted. This interpretation has important implications for treatment sequencing. Therapeutic interventions themselves may act as exertional stimuli. Oxygen therapies increase oxidative metabolism. Exercise increases mitochondrial demand. Stimulants increase neuronal firing and autonomic activation. Cognitive rehabilitation increases synaptic and attentional workload. Antiviral therapies may transiently intensify inflammatory signaling through immune activation and pathogen die off mechanisms.

Accordingly, the distinction between treatment and stress may become biologically blurred in patients with reduced adaptive reserve. Several recent studies support this interpretation indirectly. Reduced cerebral blood flow during orthostatic challenge has been repeatedly documented in ME/CFS patients despite relatively preserved systemic blood pressure, suggesting impaired neurovascular compensation (Van Campen et al., 2020). Elevated cerebrospinal fluid lactate and evidence of altered astrocyte mediated metabolic support further support the presence of impaired energetic adaptation within the central nervous system . Meanwhile, mitochondrial abnormalities, oxidative stress signatures, endothelial dysfunction, and autonomic dysregulation continue to emerge across Long COVID and ME/CFS cohorts (Tomas et al., 2017; Appelman et al., 2024). Within this framework, post exertional malaise may be understood as the visible clinical expression of exceeding an adaptive metabolic threshold.

Expanded PEM Load Domains

Load Domain	Examples
Physical	Exercise, walking, rehabilitation
Cognitive	Meetings, reading, gaming, multitasking
Sensory	Light, sound, crowded environments
Autonomic	Heat exposure, standing, tachycardia
Inflammatory	Infection, allergen exposure, immune activation
Metabolic	Hyperoxia, stimulants, mitochondrial activation
Emotional	Stress, conflict, hypervigilance

This systems level interpretation may also help explain why patient populations frequently describe temporary improvement followed by delayed collapse after interventions that initially appeared beneficial. Under Therapeutic Polarity™, the intervention itself may transiently increase function while simultaneously consuming physiologic reserve faster than the underlying terrain can sustain.

3. Iron Redox Dysregulation and the Neuro Metabolic Terrain

Iron plays a central role in oxygen transport, mitochondrial respiration, neurotransmitter synthesis, endothelial regulation, immune signaling, and neuronal energy production. However, iron biology is highly state dependent. Both deficiency and dysregulated accumulation may contribute to oxidative stress, inflammatory amplification, endothelial dysfunction, impaired mitochondrial respiration, and altered synaptic signaling (Kell, 2009; Cairo et al., 2021). In recent years, growing evidence has suggested that iron redox instability may represent an underrecognized contributor to cognitive dysfunction, exertional intolerance, and treatment variability in Long COVID and ME/CFS.

Multiple post COVID investigations have demonstrated elevated ferritin levels in patients meeting criteria for ME/CFS, with ferritin correlating with fatigue severity, depressive symptoms, and functional impairment . Importantly, these abnormalities often occur despite relatively modest conventional inflammatory markers, suggesting that altered iron handling may persist independently of overt acute phase inflammation. Ferritin itself may additionally function as an active inflammatory mediator through cytokine amplification, NF κB signaling, oxidative stress generation, and immune modulation rather than serving solely as a passive storage biomarker (Kell and Pretorius, 2014; Vargas Vargas and Cortés Roa, 2020).

Experimental evidence involving ferritin light chain 1 (FTL1) provides a potentially important mechanistic model linking iron dysregulation to neuro metabolic instability. Elevated neuronal FTL1 was associated with impaired synaptic plasticity, altered iron oxidation states, mitochondrial ATP suppression, and cognitive dysfunction in preclinical models . While current FTL1 findings remain largely preclinical, they provide a biologically plausible framework linking iron dysregulation, mitochondrial dysfunction, synaptic instability, and cognitive impairment that warrants direct investigation in human IACC populations.

Importantly, iron dysregulation may interact directly with several broader terrain abnormalities repeatedly observed across Long COVID and ME/CFS literature. These include:

• impaired cerebral perfusion

• endothelial dysfunction

• autonomic instability

• oxidative stress accumulation

• altered excitation inhibition balance

• mitochondrial ATP reduction

• neuroimmune activation

• PEM physiology

These interconnected abnormalities may collectively narrow adaptive reserve and increase susceptibility to physiologic overload during exertion, cognitive demand, inflammatory activation, or therapeutic escalation (Komaroff and Lipkin, 2021; Wirth and Scheibenbogen, 2021; Systrom et al., 2022; Davis et al., 2023).

The interaction between iron dysregulation and neurovascular instability may be especially important. Reduced cerebral perfusion may impair oxygen and substrate delivery while simultaneously increasing reliance upon inefficient glycolytic metabolism and lactate accumulation. Under such conditions, reactive oxygen species generation and mitochondrial inefficiency may become amplified during sustained cognitive or physiologic demand. Neurons operate within extremely narrow energetic margins, particularly during executive processing, sensory integration, and sustained attentional tasks. Even modest reductions in ATP availability may therefore produce disproportionate functional consequences (Magistretti and Allaman, 2018; Butterfield and Halliwell, 2019).

Mast cell activation may further intensify this terrain instability. Histamine, tryptase, cytokines, prostaglandins, and other mast cell mediators may contribute to endothelial permeability, blood brain barrier disruption, oxidative stress signaling, vasodilation instability, neuroinflammation, and autonomic dysregulation (Afrin et al., 2020; Theoharides et al., 2015). Histamine signaling additionally interacts with cerebral blood flow regulation and mitochondrial oxidative pathways, potentially amplifying cognitive vulnerability in susceptible patients. These interactions may help explain why MCAS overlap is frequently associated with sensory intolerance, cognitive volatility, orthostatic instability, and treatment sensitivity across IACC populations.

Hemolytic and vascular stress associated conditions may further destabilize iron handling. Babesia species directly infect and destroy red blood cells, producing hemolysis, oxidative stress, endothelial dysfunction, nitric oxide depletion, impaired oxygen carrying capacity, and free iron release . Similar mechanisms have been proposed in severe viral infection, thrombo-inflammatory states, endothelial injury syndromes, and microvascular dysfunction disorders (Pretorius et al., 2022; Kell et al., 2022). Under such conditions, free iron may catalyze reactive oxygen species generation through Fenton chemistry, contributing to lipid peroxidation, mitochondrial injury, and ferroptosis associated signaling pathways (Stockwell et al., 2017; Dixon et al., 2012).

Importantly, not all patients with elevated ferritin, severe PEM, or neurovascular instability demonstrate identical treatment intolerance patterns. Some patients may tolerate or benefit from therapies such as antioxidants, mitochondrial support compounds, autonomic agents, low dose neuro-modulatory therapies, or carefully titrated rehabilitation approaches despite otherwise unstable terrain features. Therapeutic Polarity therefore does not imply uniform response patterns, but rather proposes that fluctuating adaptive reserve may strongly influence intervention tolerability and directionality.

Potential candidate indicators of terrain instability may include:

• significant cerebral blood flow reduction during orthostatic challenge

• elevated ferritin despite relatively normal CRP

• delayed PEM following cognitive or physical exertion

• reaction time variability during sustained cognitive tasks

• orthostatic tachycardia or autonomic volatility

• elevated lactate or impaired metabolic recovery

• severe sensory intolerance

• prolonged recovery following physiologic stress

These candidate markers remain exploratory and require prospective validation. However, they may provide a starting framework for operationalizing adaptive reserve instability in future IACC research.

4. FTL1, Synaptic Dysfunction, and Cognitive Energy Failure

Iron Regulation Beyond Classical Iron Overload

Cognitive dysfunction in Long COVID and ME/CFS has traditionally been interpreted through broad concepts such as neuroinflammation, autonomic dysfunction, or generalized fatigue. However, emerging evidence suggests that more specific cellular mechanisms involving iron regulation, synaptic integrity, mitochondrial energetics, and neurovascular stability may contribute directly to the cognitive instability observed in infection associated chronic conditions. Among the most significant recent developments is the identification of ferritin light chain 1 (FTL1) as a mediator of neuronal dysfunction and cognitive decline.

Experimental evidence demonstrates that elevated neuronal FTL1 contributes to impaired synaptic plasticity, disrupted hippocampal long term potentiation, altered iron oxidation states, reduced mitochondrial ATP generation, and progressive cognitive impairment . Importantly, these impairments were not associated solely with classical neuronal destruction but with functional metabolic instability within neural systems. This distinction is highly relevant to Long COVID and ME/CFS, where patients frequently demonstrate fluctuating rather than fixed cognitive deficits.

Iron is essential for mitochondrial respiration, oxygen handling, neurotransmitter synthesis, and neuronal signaling. However, dysregulated iron handling may amplify oxidative stress through Fenton chemistry, reactive oxygen species generation, lipid peroxidation, and ferroptosis associated signaling pathways (Kell, 2009; Stockwell et al., 2017; Dixon et al., 2012). Excessive intracellular iron accumulation has been implicated across neurodegenerative and neuroinflammatory disorders including Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, and vascular cognitive impairment (Ward et al., 2014; Ashraf et al., 2018). Emerging evidence suggests that even moderate iron dysregulation may impair mitochondrial reserve long before overt structural degeneration becomes apparent.

The hippocampus and prefrontal cortex are particularly vulnerable to energetic instability due to their high metabolic demand and dependence on tightly coordinated neurovascular support. Synaptic transmission, working memory, executive control, and sustained attentional processing require substantial ATP availability, precise ion regulation, glutamate recycling, and astrocyte neuronal metabolic coordination. Disruption of these systems may produce cognitive slowing, attentional fragmentation, sensory overload, word retrieval difficulty, and reduced multitasking tolerance without overt neuronal death .

Cognitive Exertion as a Metabolic Stressor

This framework aligns closely with patient reported cognitive exertion intolerance in ME/CFS and Long COVID. Patients frequently describe temporary preservation of cognitive function followed by delayed neurologic worsening after sustained mental effort. Such episodes often involve:

• reduced information processing speed

• impaired verbal fluency

• memory disruption

• emotional dysregulation

• visual sensitivity

• prolonged post exertional cognitive crashes

Under conventional models these fluctuations may appear inconsistent. However, under a neuro metabolic framework, these episodes may reflect transient ATP depletion, oxidative stress accumulation, impaired oxygen utilization, unstable glutamatergic signaling, and synaptic inefficiency within already vulnerable neural networks.

Recent ME/CFS neuroimaging and neurophysiologic studies further support this interpretation. Elevated cerebrospinal fluid lactate, altered glutamate signaling, abnormal excitation inhibition balance, impaired cerebral blood flow responses, and evidence of glial activation have all been documented across subsets of patients . Astrocytes normally provide metabolic support to neurons through lactate shuttling, neurotransmitter regulation, glycogen derived substrate delivery, and neurovascular coupling (Pellerin and Magistretti, 1994; Magistretti and Allaman, 2018). Chronic inflammatory signaling, oxidative stress, endothelial dysfunction, and impaired mitochondrial performance may compromise these compensatory mechanisms, narrowing the energetic reserve available during cognitive demand.

Mitochondrial dysfunction itself has been repeatedly implicated in ME/CFS and Long COVID. Reduced ATP synthesis, impaired pyruvate dehydrogenase activity, altered oxidative phosphorylation, and increased oxidative stress signatures have been observed across patient cohorts (Tomas et al., 2017; Missailidis et al., 2021; Appelman et al., 2024). Neurons operate within extremely narrow energetic margins, particularly during sustained executive processing. Even modest reductions in mitochondrial efficiency may therefore produce disproportionate functional consequences during cognitive exertion.

FTL1, ATP Suppression, and Synaptic Instability

The relationship between FTL1 and mitochondrial dysfunction may therefore represent a mechanistic bridge connecting ferritin dysregulation, oxidative stress, synaptic instability, and cognitive post exertional malaise. Increased neuronal iron dysregulation may amplify reactive oxygen species generation, impair electron transport chain function, reduce ATP availability, and increase susceptibility to excitotoxic stress. Elevated extracellular glutamate and impaired astrocytic glutamate clearance have both been associated with neuroinflammatory cognitive dysfunction and altered excitation inhibition balance (Dong et al., 2009; Butterfield and Halliwell, 2019).

Under such conditions, interventions that increase neuronal activation or metabolic demand may temporarily enhance function while simultaneously accelerating energetic depletion. This dynamic may partially explain why patients frequently report transient cognitive improvement followed by delayed neurologic worsening after stimulants, prolonged concentration, cognitive rehabilitation, hyperbaric oxygen exposure, emotionally intense interactions, or sustained sensory engagement. Importantly, experimental reversal of FTL1 related cognitive impairment through NADH associated metabolic support suggests that at least part of this dysfunction may remain biologically modifiable rather than permanently degenerative . This distinction is critical because it supports the broader hypothesis that cognitive dysfunction in IACCs reflects unstable adaptive physiology rather than inevitable structural decline.

Implications for Therapeutic Sequencing

Such findings also carry implications for therapeutic sequencing. Interventions designed to increase cognitive performance, mitochondrial output, neuronal firing, or oxygen utilization may produce sharply divergent outcomes depending on baseline energetic reserve and oxidative stability.

Potential examples include:

• stimulants temporarily improving executive function before triggering sympathetic overactivation

• oxygen based therapies improving cognition while intensifying oxidative burden in vulnerable terrain states

• aggressive cognitive rehabilitation provoking delayed PEM related crashes

• mitochondrial activating compounds increasing short term performance while accelerating energetic depletion

• iron supplementation improving oxygen carrying capacity in one patient while worsening oxidative stress in another

Under Therapeutic Polarity™, these divergent outcomes may represent predictable biologic responses to differing terrain states rather than treatment inconsistency alone.

5. Neurovascular Compensation and Cerebral Perfusion Instability

Normal cognition depends upon continuous coordination between neuronal activity, vascular regulation, oxygen delivery, glucose metabolism, autonomic control, endothelial signaling, and glial support. This process, commonly referred to as neurovascular coupling, allows active brain regions to rapidly increase local blood flow and substrate delivery during cognitive demand. In ME/CFS and Long COVID, growing evidence suggests that this adaptive system becomes impaired, reducing the brain’s ability to compensate for metabolic stress during exertion, sustained attention, orthostatic challenge, inflammatory activation, and sensory overload.

Multiple neuroimaging studies demonstrate reduced cerebral blood flow in ME/CFS patients both at baseline and during orthostatic stress . Importantly, these reductions frequently occur despite relatively preserved systemic blood pressure, suggesting dysregulation of cerebrovascular autoregulation rather than simple systemic hypotension (Van Campen et al., 2020). Functional MRI, arterial spin labeling, SPECT imaging, and autonomic challenge studies collectively support the presence of impaired neurovascular responsiveness, altered perfusion dynamics, and inefficient oxygen substrate delivery across cognitive networks (Biswal et al., 2011; Shan et al., 2020).

This impaired perfusion may have major implications for cognitive exertion tolerance. Neurons possess limited intrinsic energy reserves and depend heavily upon rapid delivery of oxygen and glucose during periods of sustained activity. Astrocytes help regulate this process through calcium signaling, vascular modulation, glutamate recycling, nitric oxide associated signaling, and lactate production. However, chronic inflammation, oxidative stress, endothelial dysfunction, mitochondrial impairment, and autonomic instability may compromise astrocyte mediated neurovascular support .

Endothelial dysfunction appears increasingly relevant across Long COVID and ME/CFS. Reduced flow mediated dilation, altered nitric oxide bioavailability, impaired vascular relaxation, and microvascular instability have all been reported in post viral cohorts (Charfeddine et al., 2021; Sokolakis et al., 2023). Emerging microvascular and clotting studies additionally suggest that endothelial inflammation, altered blood rheology, fibrin associated abnormalities, and impaired capillary exchange may contribute to tissue hypoperfusion and exertional intolerance (Pretorius et al., 2022; Kell et al., 2022). While causal pathways remain under investigation, the cumulative evidence supports the presence of an unstable vascular terrain vulnerable to physiologic overload.

Under such conditions, cognitive demand itself may become metabolically destabilizing. Tasks requiring sustained executive function, information processing, emotional regulation, visual tracking, or multitasking may exceed local compensatory capacity, producing transient hypoperfusion, increased glycolytic stress, elevated lactate accumulation, and synaptic inefficiency. This model is highly consistent with patient reports of delayed cognitive collapse following prolonged concentration, meetings, gaming, writing, sensory exposure, or emotionally intense interactions. Importantly, cerebral perfusion instability may also interact directly with iron redox biology. Reduced oxygen delivery and impaired mitochondrial respiration increase reliance upon inefficient metabolic pathways, which may further amplify reactive oxygen species generation and oxidative injury. Endothelial dysfunction may additionally impair nitric oxide signaling, vascular relaxation, and microcirculatory responsiveness, further narrowing the adaptive metabolic window available during exertional stress.

Several investigations also suggest possible transient blood brain barrier instability and neurovascular unit dysfunction in ME/CFS and Long COVID . Cytokine mediated endothelial stress, oxidative injury, mast cell activation, and inflammatory signaling may increase vascular permeability and amplify neuroimmune activation (Erickson and Banks, 2018; Varatharaj and Galea, 2017). Even subtle blood brain barrier dysfunction may permit peripheral inflammatory mediators to interact more directly with glial and neuronal systems, potentially intensifying cognitive instability during flare states.

This interpretation may also help explain the inconsistent response patterns observed with oxygen based interventions. Hyperbaric oxygen therapy demonstrated statistically significant improvements in fatigue, executive function, attention, processing speed, and global cognition in an early Long COVID cohort . However, many patients with severe autonomic dysfunction, mast cell activation, oxidative sensitivity, or PEM dominant disease report worsening symptoms after oxygen based or hypermetabolic therapies.

Under Therapeutic Polarity™, these divergent outcomes are not contradictory. Instead, they may reflect differing baseline terrain states. Increased oxygen availability may improve ATP generation and cerebral function in one patient while simultaneously intensifying oxidative stress, inflammatory signaling, endothelial instability, or excitatory burden in another. Accordingly, neurovascular dysfunction should not be viewed solely as a downstream consequence of chronic illness. It may instead function as a central regulator of cognitive reserve, exertional tolerance, and therapeutic stability across IACCs.

6. Therapeutic Polarity and Adaptive Metabolic Windows

Conventional biomedical models frequently assume that therapeutic benefit scales linearly with intervention intensity. Under this framework, greater exercise should improve conditioning, increased oxygen delivery should improve energy production, and intensified cognitive rehabilitation should strengthen neuroplastic recovery. However, Long COVID and ME/CFS repeatedly challenge this assumption through highly nonlinear treatment responses characterized by temporary improvement followed by delayed physiologic deterioration.

Patients with infection associated chronic conditions frequently report that interventions initially associated with benefit later trigger cognitive collapse, autonomic worsening, inflammatory flares, sensory overload, sleep disruption, or prolonged PEM amplification. Similar therapies may simultaneously help some patients while destabilizing others. These patterns are often interpreted as inconsistency, psychosomatic amplification, placebo response, or poor compliance. Yet the reproducibility of these observations across diverse interventions and patient populations suggests the presence of a broader biologic mechanism involving fluctuating adaptive reserve. Therapeutic Polarity proposes that treatment response in IACCs is governed by adaptive metabolic windows rather than fixed intervention categories. Within this framework, each patient possesses a fluctuating physiologic range within which exertion, immune activation, oxygen utilization, cognitive demand, autonomic stimulation, and mitochondrial throughput can be tolerated without triggering destabilization. Outside this adaptive window, the same intervention may transition from restorative support into physiologic stress.

This interpretation aligns with broader concepts involving allostasis, hormesis, mitochondrial reserve physiology, and nonlinear stress adaptation (Sterling and Eyer, 1988; McEwen, 1998; Calabrese, 2008; Naviaux, 2019). Similar reserve dependent response patterns have been observed across traumatic brain injury recovery, critical illness rehabilitation, mitochondrial disease, autoimmune illness, overtraining syndromes, and neurodegenerative disease states in which excessive physiologic demand may worsen dysfunction despite theoretically beneficial intervention intent.

Long COVID and ME/CFS appear particularly vulnerable to such reserve instability due to the convergence of impaired cerebral perfusion, endothelial dysfunction, autonomic dysregulation, mitochondrial inefficiency, oxidative stress accumulation, neuroimmune activation, and PEM physiology (Komaroff and Lipkin, 2021; Davis et al., 2023; Systrom et al., 2022). Neurovascular investigations demonstrate impaired cerebral blood flow responses during orthostatic challenge and cognitive demand . Mitochondrial studies reveal reduced ATP generation, altered oxidative phosphorylation, and impaired metabolic recovery (Tomas et al., 2017; Missailidis et al., 2021). Ferritin and FTL1 associated findings further suggest that unstable iron handling may amplify oxidative burden and synaptic vulnerability .

Under such conditions, interventions increasing oxygen consumption, neuronal activation, immune signaling, mitochondrial throughput, autonomic demand, or cognitive workload may temporarily improve function while simultaneously accelerating energetic depletion or oxidative stress accumulation. Exercise based rehabilitation may improve autonomic conditioning in one patient while provoking severe PEM in another. Hyperbaric oxygen may improve cognition and fatigue in selected patients while worsening oxidative instability in those with impaired redox reserve . Stimulants may transiently restore executive function before precipitating sympathetic overactivation and cognitive collapse. Cognitive rehabilitation may strengthen neuroplastic recovery under stable conditions while provoking neurovascular overload during active flare states.

Importantly, Therapeutic Polarity does not suggest that treatments themselves are inherently harmful. Rather, it proposes that therapeutic efficacy and tolerability are context dependent. A therapy introduced during active inflammatory volatility, autonomic destabilization, endothelial dysfunction, or oxidative overload may produce substantially different outcomes compared with the same intervention administered after partial physiologic stabilization. This framework may additionally help explain why pacing strategies remain clinically valuable despite ongoing controversy regarding their interpretation. Pacing may function not merely as symptom avoidance, but as adaptive reserve preservation during periods of impaired neuro metabolic compensation (Nijs et al., 2013; Davenport et al., 2019). Similarly, rehabilitation tolerance may depend less upon patient motivation or deconditioning status and more upon whether current physiologic reserve can safely absorb additional metabolic demand.

Operationalizing stable versus unstable terrain states remains an important future challenge. Potential indicators may include cerebral blood flow variability during orthostatic challenge, ferritin abnormalities, reaction time drift during sustained cognitive tasks, autonomic volatility, PEM recovery duration, endothelial function markers, sleep fragmentation, or metabolic recovery abnormalities. These markers remain exploratory but may provide future pathways for adaptive treatment modeling and physiologic stratification. Under Therapeutic Polarity, variability in treatment response becomes biologically meaningful rather than statistically inconvenient. Intervention success may depend not solely upon selecting the correct therapy, but upon determining when the underlying terrain possesses sufficient reserve to tolerate that intervention safely.

7. Digital Biomarkers, Gaming, and Functional Drift Detection

Beyond Static Cognitive Testing

One of the greatest challenges in Long COVID and ME/CFS research is that physiologic deterioration often becomes clinically visible only after substantial functional decline has already occurred. Traditional clinical assessments frequently rely upon static snapshots such as laboratory testing, isolated office evaluations, subjective symptom recall, or infrequent neuropsychological testing. However, infection associated chronic conditions are highly dynamic illnesses characterized by fluctuating reserve capacity, delayed symptom amplification, and state dependent cognitive instability. As a result, conventional assessment tools may fail to capture the early stages of terrain destabilization preceding overt PEM or cognitive collapse.

Digital biomarker systems may provide an important solution to this limitation. Gaming environments, sustained interactive tasks, reaction time analysis, precision tracking, and continuous behavioral monitoring offer opportunities to detect subtle neurocognitive instability in real time before severe symptom escalation occurs. Unlike traditional testing environments, gaming based systems repeatedly stress attentional processing, motor coordination, executive function, visual tracking, working memory, sensory integration, and autonomic responsiveness over prolonged intervals. This makes them uniquely suited for identifying dynamic deterioration patterns associated with adaptive reserve depletion.

The use of digital behavioral metrics has expanded rapidly across neurology, psychiatry, rehabilitation medicine, and neurodegenerative disease research (Insel, 2017; Dagum, 2018). Continuous performance variability, rather than isolated peak performance, increasingly appears relevant for detecting subtle neurologic dysfunction in disorders involving impaired cognitive endurance, autonomic instability, or fluctuating metabolic reserve (Sternberg et al., 2013; Rutkove et al., 2020).

Functional Drift and Neuro Metabolic Instability

The CYNAERA gaming and digital biomarker framework proposes that functional drift may represent one of the earliest detectable signatures of impending physiologic destabilization. Rather than focusing solely upon peak performance, this model emphasizes variability, instability, inconsistency, recovery lag, and progressive decline under sustained load. Patients may initially maintain normal or near normal performance before gradually demonstrating slowing reaction times, increased error rates, shortened endurance, reduced multitasking capacity, impaired decision speed, sensory overload, task abandonment, or delayed post activity crashes.

This interpretation aligns with broader neurophysiologic findings in ME/CFS and Long COVID. Impaired cerebral blood flow regulation, altered excitation inhibition balance, mitochondrial ATP reduction, neurovascular instability, autonomic dysfunction, and oxidative stress may all reduce the nervous system’s ability to sustain prolonged cognitive demand . Under these conditions, performance instability may emerge before overt structural deficits become detectable through standard clinical evaluation.

Cognitive fatigue studies in ME/CFS have repeatedly demonstrated worsening reaction time consistency, attentional decline, reduced processing efficiency, and impaired sustained cognitive output during prolonged tasks (Cockshell and Mathias, 2010; Tanaka et al., 2002). Similar variability patterns have also emerged in concussion research, neurodegenerative disease modeling, and autonomic dysfunction studies where dynamic reserve failure often precedes fixed structural decline (Covassin et al., 2012; Lim et al., 2019). Importantly, digital biomarker systems may also provide a means of operationalizing Therapeutic Polarity™. If interventions alter metabolic demand, oxidative burden, neurovascular reserve, or autonomic stress tolerance, then subtle shifts in digital performance may serve as early indicators of whether a treatment is stabilizing or destabilizing the underlying terrain.

Cognitive Load as Controlled Stress Testing

Under this framework, gaming and sustained cognitive interaction environments function less as entertainment platforms and more as controlled neurocognitive stress testing systems. Continuous attentional demand, sensory integration, rapid decision making, motor precision, and executive switching may reveal adaptive reserve instability long before conventional testing identifies measurable impairment. Neurovascular and mitochondrial limitations may become especially apparent during prolonged or multitask heavy environments. Cognitive effort increases ATP consumption, glutamatergic signaling, cerebral oxygen demand, and neurovascular coupling requirements. In patients with impaired compensatory reserve, this increased demand may progressively narrow adaptive metabolic windows and eventually trigger post exertional cognitive deterioration.

Importantly, this deterioration may not appear immediately. Similar to physical PEM, cognitive overload may produce delayed symptom amplification involving:

• executive dysfunction

• visual sensitivity

• autonomic worsening

• slowed information processing

• emotional dysregulation

• sleep disruption

• prolonged recovery periods

This delayed deterioration pattern mirrors broader PEM physiology observed in ME/CFS and Long COVID and further supports the possibility that cognitive exertion itself represents a biologically meaningful metabolic stressor rather than a purely psychological phenomenon (Institute of Medicine, 2015; Davenport et al., 2019).

Implications for Precision Monitoring

Digital biomarker systems may therefore hold important implications for precision medicine and clinical trial design. Current therapeutic studies often rely upon infrequent symptom questionnaires or isolated office assessments that may fail to capture transient destabilization events, delayed PEM responses, or adaptive reserve depletion.

Continuous or longitudinal digital monitoring may improve the ability to:

• detect early treatment destabilization

• identify PEM thresholds

• monitor treatment tolerability longitudinally

• stratify patients by cognitive reserve state

• identify high risk flare periods

• personalize rehabilitation pacing

• quantify therapeutic volatility

Importantly, this model does not suggest that gaming itself is inherently therapeutic or harmful. Rather, gaming environments may provide uniquely sensitive windows into the neuro metabolic terrain, revealing instability patterns that remain largely invisible through conventional assessment paradigms.

8. Therapeutic Sequencing and the Stabilization First Model

Current treatment paradigms for Long COVID and ME/CFS frequently emphasize isolated interventions directed toward individual symptoms or presumed primary mechanisms. Patients may therefore receive exercise rehabilitation, antivirals, autonomic agents, stimulants, oxygen therapies, cognitive rehabilitation, mast cell therapies, mitochondrial supplements, anticoagulants, or immunomodulators without sufficient consideration of underlying terrain stability or adaptive reserve. However, the Therapeutic Polarity™ framework suggests that intervention order itself may significantly influence treatment outcome.

Under this model, stabilization becomes a prerequisite for escalation rather than a secondary consideration. A patient operating near physiologic threshold may not tolerate therapies that increase oxygen demand, neuronal activation, mitochondrial throughput, autonomic stress, or inflammatory signaling even when those interventions may ultimately prove beneficial under more stable conditions.

This concept aligns with broader biologic principles observed across critical illness recovery, mitochondrial disease, concussion rehabilitation, autonomic disorders, and exercise physiology. In systems operating near adaptive limit, excessive physiologic demand may trigger secondary destabilization despite otherwise beneficial intervention intent (Naviaux, 2019; Brosschot et al., 2018). Infection associated chronic conditions may represent an analogous state in which reduced reserve narrows the range of tolerable therapeutic escalation.

Potential stabilization targets before escalation may include:

• autonomic regulation

• endothelial stabilization

• mast cell control

• sleep restoration

• oxidative stress reduction

• inflammatory load reduction

• cerebral perfusion support

• nutritional stabilization

• sensory load management

• pacing and PEM threshold reduction

Once baseline instability is reduced, additional interventions may become more tolerable and potentially more effective. For example, a patient unable to tolerate cognitive rehabilitation during severe autonomic instability may later tolerate graded cognitive demand after endothelial stabilization and PEM reduction. Similarly, mitochondrial therapies that initially provoke oxidative stress may become more effective once inflammatory volatility and neurovascular instability are partially controlled.

This sequencing framework may also help explain why patients frequently report contradictory responses to the same therapies across different phases of illness. Interventions that initially triggered worsening may later become beneficial after stabilization of vascular, autonomic, inflammatory, or metabolic terrain. Conversely, therapies tolerated during relatively stable periods may become destabilizing during flare states or active infectious reactivation. The concept of sequencing may be particularly important in relation to therapies involving increased metabolic throughput. Oxygen based interventions, mitochondrial stimulants, exercise rehabilitation, stimulants, immune activation therapies, and cognitive training all increase physiologic demand to varying degrees. In patients with impaired ATP reserve, neurovascular instability, or oxidative vulnerability, these interventions may exceed adaptive capacity if introduced prematurely.

This framework additionally supports the possibility that some failed therapies in Long COVID and ME/CFS may not represent incorrect therapies but incorrect timing. A therapy administered during active inflammatory volatility, autonomic destabilization, or oxidative overload may produce dramatically different outcomes compared with the same intervention administered after partial stabilization. Accordingly, Therapeutic Polarity™ reframes treatment tolerance as a dynamic biologic variable rather than a fixed patient characteristic. Intervention sequencing, terrain stabilization, and reserve assessment may therefore become central components of future precision medicine strategies in IACCs.

9. Therapeutic Polarity™, Precision Medicine, and Future Clinical Trial Design

One of the most persistent challenges in Long COVID and ME/CFS therapeutics is the reproducibility crisis surrounding intervention efficacy. Treatments that appear highly effective in some patients may produce no benefit or substantial worsening in others. This variability has contributed to conflicting rehabilitation recommendations, inconsistent clinical trial outcomes, elevated dropout rates, and persistent skepticism surrounding post infectious chronic disease therapeutics. Conventional clinical trial models often assume relative physiologic stability within disease categories. However, Therapeutic Polarity™ proposes that patients with IACCs may occupy highly variable terrain states defined by fluctuating neurovascular reserve, mitochondrial capacity, oxidative burden, autonomic stability, inflammatory activity, and PEM threshold sensitivity. Under such conditions, averaging outcomes across biologically heterogeneous populations may obscure subgroup specific benefit while simultaneously amplifying adverse event variability.

This interpretation aligns with broader trends in precision medicine emphasizing biologic stratification, adaptive response modeling, and individualized physiologic profiling (Collins and Varmus, 2015). In oncology, immunology, neurology, and critical care medicine, increasing recognition has emerged that treatment response depends heavily upon underlying biologic state rather than diagnosis alone (Topol, 2014; Ashley, 2016). Long COVID and ME/CFS may require a similar transition away from static diagnostic categorization toward dynamic terrain based modeling.

Within this framework, future clinical trial design may benefit from integrating cerebral perfusion analysis, autonomic profiling, ferritin and iron handling markers, endothelial function assessment, oxidative stress biomarkers, mitochondrial reserve measures, PEM threshold analysis, and longitudinal variability tracking rather than relying exclusively upon static symptom scoring. Such approaches may improve identification of patients most likely to tolerate or respond to specific interventions while simultaneously reducing destabilization risk in vulnerable subgroups.

Digital biomarker systems may prove particularly valuable in this context. Reaction time drift, endurance decline, cognitive variability, multitasking tolerance, and delayed recovery signatures may provide more sensitive indicators of therapeutic destabilization than isolated office based testing or symptom questionnaires. Continuous monitoring systems may also improve detection of delayed PEM related deterioration that frequently occurs outside conventional assessment windows. Importantly, Therapeutic Polarity™ may also help reinterpret negative clinical trial outcomes. Under this framework, lack of benefit across a heterogeneous population does not necessarily imply lack of biologic efficacy. Instead, subgroup specific benefit may be obscured by terrain mismatch, improper sequencing, physiologic overload, or instability induced by the intervention itself.

Similar issues have emerged across rehabilitation medicine, oncology, neurodegeneration, and immunotherapy where highly heterogeneous biologic response states complicate interpretation of aggregate trial outcomes (Joyner and Paneth, 2019; Calabrese, 2008). Long COVID and ME/CFS may represent particularly sensitive examples due to the combination of neurovascular instability, PEM physiology, autonomic dysfunction, mitochondrial impairment, and fluctuating inflammatory burden.

This perspective may carry substantial implications for future therapeutic development in Long COVID, ME/CFS, dysautonomia, mast cell disorders, and related IACCs. Rather than focusing exclusively upon identifying universally effective therapies, future approaches may increasingly prioritize identifying optimal intervention timing, stabilizing terrain before escalation, stratifying patients by reserve state, monitoring dynamic physiologic response, preventing treatment induced destabilization, and adapting interventions to fluctuating biologic states. Under this framework, variability itself becomes clinically meaningful rather than statistically inconvenient. Therapeutic Polarity™ therefore proposes a broader shift in chronic disease medicine. The central question may no longer be simply whether a treatment works, but under what physiologic conditions, sequencing states, and adaptive reserve thresholds that treatment remains therapeutic rather than becoming stress.

10. Ferritin, Hemolysis, and Infection Associated Terrain Destabilization

Iron dysregulation in infection associated chronic conditions may extend beyond isolated mitochondrial dysfunction or neuronal oxidative stress. Increasing evidence suggests that persistent inflammatory activation, endothelial dysfunction, viral persistence, vascular injury, autonomic instability, and hemolytic processes may collectively contribute to unstable iron handling states capable of amplifying systemic physiologic vulnerability.

Ferritin has historically been interpreted primarily as a biomarker of iron storage or acute inflammation. However, contemporary evidence increasingly supports a more active biologic role involving cytokine signaling, oxidative stress amplification, immune modulation, endothelial activation, and metabolic regulation (Kell and Pretorius, 2014; Cairo et al., 2021). Elevated ferritin levels have been repeatedly associated with severe COVID 19, hyperinflammatory states, endothelial dysfunction, thromboinflammatory activation, and oxidative stress related injury (Vargas Vargas and Cortés Roa, 2020; Gómez Pastor et al., 2020).

In Long COVID and ME/CFS populations, ferritin elevations frequently occur even when conventional inflammatory markers remain relatively modest . This observation raises the possibility that altered iron handling may persist independently of overt acute phase inflammatory signaling. Such dysregulation may contribute to oxidative vulnerability, impaired mitochondrial efficiency, endothelial instability, altered nitric oxide signaling, and neurovascular compensation failure long after the initial infectious trigger.

Mast cell activation may further contribute to this terrain instability. Histamine mediated vasodilation, cytokine release, oxidative signaling, endothelial permeability changes, and blood brain barrier disruption may amplify autonomic dysfunction and neurovascular volatility (Theoharides et al., 2015; Afrin et al., 2020). Mast cell mediators may additionally interact with iron redox biology and mitochondrial stress pathways, potentially intensifying cognitive dysfunction, sensory intolerance, orthostatic instability, and PEM vulnerability in susceptible patients.

Hemolytic and vascular stress associated conditions may further destabilize iron handling states. Babesia species directly infect and destroy red blood cells, producing hemolysis, endothelial stress, inflammatory activation, nitric oxide depletion, impaired oxygen transport, and free iron release . Similar mechanisms have also been proposed across severe viral infection, thrombo-inflammatory syndromes, microvascular injury states, and endothelial dysfunction disorders (Pretorius et al., 2022; Kell et al., 2022). Importantly, free iron itself may become biologically destabilizing under conditions of impaired redox regulation. Iron catalyzes reactive oxygen species generation through Fenton chemistry, contributing to lipid peroxidation, mitochondrial injury, endothelial dysfunction, and ferroptosis associated signaling pathways (Stockwell et al., 2017; Dixon et al., 2012). In tissues already operating near metabolic threshold, such oxidative amplification may further narrow adaptive reserve.

This framework may help explain why some IACC patients experience disproportionate neurologic, autonomic, vascular, or exertional instability despite relatively nonspecific laboratory findings. Standard complete blood counts or ferritin ranges may fail to capture localized tissue iron dysregulation, endothelial oxidative stress, mitochondrial vulnerability, or fluctuating redox instability occurring at the cellular level. Importantly, not all patients with elevated ferritin or severe PEM demonstrate identical treatment sensitivity. Some individuals tolerate mitochondrial supports, antioxidants, autonomic therapies, carefully titrated exercise, or neuromodulatory agents despite otherwise unstable terrain characteristics. This heterogeneity reinforces the central premise of Therapeutic Polarity: treatment response is dynamic, state dependent, and influenced by multiple interacting physiologic systems rather than by single biomarkers alone.

The interaction between iron dysregulation and cerebral perfusion instability may nevertheless remain highly important. Reduced oxygen delivery, endothelial dysfunction, impaired nitric oxide signaling, and altered mitochondrial respiration may collectively increase reliance upon inefficient glycolytic metabolism, amplifying lactate accumulation and oxidative stress during exertion. Under such conditions, therapies increasing metabolic throughput may temporarily improve function while simultaneously intensifying underlying instability.

This interpretation aligns with broader evidence linking iron dysregulation to neurodegenerative disease, vascular cognitive impairment, traumatic brain injury, and inflammatory neuroimmune disorders (Ward et al., 2014; Ashraf et al., 2018; Iadecola, 2017). Long COVID and ME/CFS may therefore represent additional conditions in which unstable iron handling contributes to progressive neuro metabolic dysfunction despite limited overt structural pathology.

11. Reframing Cognitive PEM and Neuroimmune Recovery

Cognitive dysfunction in Long COVID and ME/CFS has often been described using generalized terms such as brain fog, fatigue, or concentration difficulty. However, accumulating evidence suggests that these impairments may represent measurable disturbances in neuroenergetics, neurovascular compensation, synaptic stability, and adaptive reserve rather than nonspecific subjective symptoms alone.

The concept of cognitive PEM provides a particularly important framework for understanding these dynamics. Patients frequently report delayed worsening following sustained mental activity, emotional stress, sensory overload, prolonged meetings, multitasking, writing, gaming, or visually complex environments. These episodes may involve slowed processing speed, executive dysfunction, emotional dysregulation, visual sensitivity, autonomic worsening, sleep disruption, and prolonged recovery periods extending far beyond the original cognitive task.

Such patterns are difficult to reconcile with conventional deconditioning models alone. Instead, they suggest impaired physiologic recovery following sustained neurocognitive demand. Neuroimaging and neurophysiologic studies increasingly support this interpretation through findings involving altered cerebral blood flow, glial activation, elevated cerebrospinal fluid lactate, impaired neurovascular coupling, excitation inhibition imbalance, endothelial dysfunction, and mitochondrial instability .

Importantly, this framework also challenges assumptions that cognitive dysfunction in IACCs necessarily reflects irreversible degeneration. Experimental FTL1 data demonstrated that cognitive impairment associated with iron mediated mitochondrial dysfunction may remain at least partially reversible through metabolic support interventions . Similar reversibility patterns have been observed across concussion rehabilitation, neuroinflammatory recovery, mitochondrial disease, and certain neurovascular syndromes where functional restoration occurs despite prolonged physiologic instability (Giza and Hovda, 2014; Naviaux, 2019).

This distinction carries substantial implications for rehabilitation strategy. Under Therapeutic Polarity™, recovery may depend less upon forcing increased output and more upon expanding adaptive reserve gradually while minimizing destabilizing physiologic stress. Aggressive rehabilitation introduced during unstable terrain states may worsen oxidative burden, autonomic dysfunction, endothelial instability, or PEM amplification even when the same interventions may later become beneficial after stabilization. This perspective may also help explain why pacing strategies remain clinically valuable despite controversy surrounding their interpretation. Pacing may function not merely as symptom avoidance but as physiologic reserve preservation during periods of impaired neuro metabolic compensation. By reducing repeated threshold exceedance, pacing may theoretically reduce oxidative amplification, neurovascular overload, inflammatory activation, and mitochondrial stress accumulation.

Emerging evidence from autonomic medicine, exercise physiology, and neurorehabilitation increasingly supports the importance of graded adaptive recovery rather than continuous physiologic escalation (Nijs et al., 2013; Davenport et al., 2019). However, the Therapeutic Polarity™ framework suggests that rehabilitation tolerability may vary dramatically according to current reserve state, oxidative burden, endothelial stability, and inflammatory volatility. Accordingly, cognitive recovery in IACCs may require approaches emphasizing stabilization, adaptive reserve expansion, and longitudinal monitoring rather than static assumptions regarding exercise tolerance or rehabilitation capacity. Under this framework, cognitive instability itself becomes a measurable physiologic phenomenon reflecting fluctuating terrain integrity rather than merely subjective symptom amplification.

12. Toward a Terrain Based Model of Chronic Disease Medicine

The implications of Therapeutic Polarity™ extend beyond Long COVID and ME/CFS alone. Increasing evidence across neurology, immunology, endocrinology, rehabilitation medicine, oncology, and systems biology suggests that chronic disease states may involve fluctuating adaptive reserve rather than static physiologic dysfunction. Under such conditions, treatment outcome may depend not only upon the intervention itself but upon the biologic terrain into which the intervention is introduced.

Conventional reductionist models frequently conceptualize disease through isolated pathways or singular mechanistic targets. However, infection associated chronic conditions repeatedly demonstrate overlapping dysfunction involving mitochondrial energetics, endothelial signaling, autonomic regulation, neurovascular compensation, immune modulation, oxidative stress, and metabolic reserve. These systems interact dynamically rather than independently.

The terrain based framework proposed here suggests that therapeutic response emerges from the interaction between:

• physiologic reserve

• inflammatory load

• oxidative stability

• autonomic regulation

• endothelial integrity

• mitochondrial capacity

• neurovascular compensation

• PEM threshold sensitivity

• adaptive recovery potential

Under this model, identical interventions may produce sharply divergent outcomes depending upon systems level state at the time of administration. This interpretation aligns with broader developments in systems biology and network medicine emphasizing dynamic physiologic interaction over isolated organ pathology (Barabási et al., 2011; Loscalzo and Barabási, 2011). Similar concepts have emerged across oncology, critical care medicine, neurodegeneration, and immunotherapy where treatment response increasingly depends upon biologic context, timing, reserve state, and adaptive compensation rather than diagnosis alone.

Importantly, Therapeutic Polarity™ does not reject conventional therapeutics. Rather, it reframes therapeutic efficacy as context dependent. Exercise, oxygen therapies, antivirals, stimulants, mitochondrial agents, autonomic therapies, immune modulation, and cognitive rehabilitation may all retain important clinical value under appropriate terrain conditions. The central question becomes not whether a therapy works universally, but under which physiologic states it remains stabilizing rather than destabilizing. This perspective may help explain why so many patients with IACCs report contradictory experiences with the same therapies across different phases of illness. Terrain states are not fixed. Neurovascular reserve, inflammatory burden, oxidative stability, autonomic compensation, and PEM thresholds may fluctuate over time in response to infection, stress, environmental exposure, hormonal shifts, sleep disruption, sensory overload, or cumulative exertion.

Accordingly, future chronic disease medicine may increasingly require dynamic physiologic modeling rather than static treatment algorithms. Longitudinal biomarker monitoring, neurovascular assessment, digital functional tracking, autonomic profiling, PEM threshold identification, and adaptive reserve analysis may ultimately become central components of precision therapeutics in complex chronic disease. Within this framework, variability itself becomes biologically meaningful. Fluctuation, delayed deterioration, nonlinear recovery, and treatment sensitivity may represent critical indicators of terrain instability rather than noise to be eliminated from analysis. Therapeutic Polarity™ therefore proposes a broader conceptual shift in medicine. Chronic illness may not simply represent broken physiology, but unstable adaptive physiology operating within narrowed reserve margins. Under such conditions, treatment becomes inseparable from timing, sequencing, biologic context, and terrain state.

13. State Dependent Therapeutic Reversal

One of the most clinically recognizable features of infection associated chronic conditions is the phenomenon in which an intervention initially improves symptoms before later producing worsening, destabilization, or prolonged PEM amplification. Patients frequently report that therapies once tolerated later become intolerable, while previously destabilizing interventions may become beneficial after periods of physiologic stabilization. Conventional biomedical models often interpret these reversals as inconsistency, placebo response, psychosomatic amplification, or patient noncompliance. However, the reproducibility of these patterns across diverse therapies and disease states suggests a broader biologic mechanism involving fluctuating adaptive reserve.

Under Therapeutic Polarity™, these reversals are interpreted as state dependent shifts in physiologic tolerance. Therapeutic directionality may change according to mitochondrial reserve, endothelial stability, autonomic regulation, inflammatory burden, oxidative stress accumulation, neurovascular compensation, and PEM threshold sensitivity. This interpretation is consistent with broader literature on allostasis, hormesis, autonomic regulation, mitochondrial signaling, and nonlinear stress response biology, where the physiologic effect of a stimulus depends heavily upon dose, timing, baseline reserve, and cumulative load (Sterling and Eyer, 1988; McEwen, 1998; Calabrese, 2008; Naviaux, 2019).

In Long COVID and ME/CFS, this state dependence is especially plausible because the underlying terrain is already characterized by impaired energy metabolism, altered cerebral perfusion, autonomic dysregulation, neuroimmune activation, endothelial dysfunction, and PEM physiology (Institute of Medicine, 2015; Komaroff and Lipkin, 2021; Davis et al., 2023; Appelman et al., 2024). The 2026 neurovascular and synaptic review of ME/CFS cognitive dysfunction similarly supports a model in which cognitive symptoms reflect potentially modifiable neuroimmune and neurometabolic dysregulation rather than fixed structural degeneration alone .

State Dependent Therapeutic Reversal

Intervention	More Stable Terrain State	Unstable Terrain State
Exercise rehabilitation	Improved conditioning and autonomic tone	PEM amplification and metabolic collapse
Hyperbaric oxygen	Improved cognition and ATP support	Oxidative stress and autonomic destabilization
Stimulants	Enhanced executive function	Sympathetic overactivation and cognitive crash
Antivirals	Reduced pathogen burden	Immune volatility and inflammatory flare
Cognitive rehabilitation	Neuroplastic support	Neurovascular overload and delayed PEM
Iron supplementation	Improved oxygen transport	Oxidative injury and endothelial stress

Importantly, this framework does not imply that treatments themselves are intrinsically beneficial or harmful. Rather, intervention outcome becomes conditional upon biologic context. Identical therapies may therefore produce opposite clinical effects depending upon terrain stability at the time of administration. This is supported conceptually by exercise intolerance studies in ME/CFS, post exertional symptom exacerbation research, autonomic dysfunction studies, and rehabilitation literature showing that therapeutic loading must be adapted to physiologic tolerance rather than assumed safe across all patients (Davenport et al., 2019; Van Campen et al., 2020; Nijs et al., 2013; Systrom et al., 2022).

This interpretation may also help explain inconsistent rehabilitation literature across Long COVID and ME/CFS. Interventions appearing ineffective or harmful in aggregate populations may still retain substantial subgroup specific benefit under appropriate sequencing conditions. Conversely, therapies demonstrating initial benefit may still contribute to delayed deterioration if physiologic demand persistently exceeds adaptive reserve. HBOT offers a useful example because early Long COVID data showed improvements in fatigue and cognitive domains, while the Therapeutic Polarity™ framework would predict that oxygen based interventions may still destabilize patients with severe oxidative vulnerability, mast cell activation, endothelial instability, or iron redox dysregulation. Under Therapeutic Polarity™, treatment reversibility itself becomes clinically meaningful. Shifting tolerance patterns may reflect dynamic changes in terrain integrity rather than random variability alone.

14. Implications for Long COVID, ME/CFS, and Broader IACCs

Although this framework has focused primarily upon Long COVID and ME/CFS, the broader principles underlying Therapeutic Polarity™ may extend across multiple infection associated and neuroimmune conditions involving fluctuating physiologic reserve. Increasing evidence suggests that chronic illnesses previously categorized as distinct entities frequently share overlapping features involving mitochondrial dysfunction, autonomic instability, endothelial impairment, neurovascular dysregulation, oxidative stress, mast cell activation, impaired oxygen utilization, and impaired recovery following exertional challenge (Komaroff and Lipkin, 2021; Wirth and Scheibenbogen, 2021; Systrom et al., 2022; Proal and VanElzakker, 2021).

This shared terrain may include Long COVID, ME/CFS, dysautonomia, mast cell activation syndrome, chronic Lyme disease and post treatment Lyme disease syndrome, mold associated illness, post sepsis syndromes, autoimmune neuroinflammatory disorders, traumatic brain injury recovery states, and chronic viral reactivation syndromes. While these conditions remain biologically heterogeneous, many demonstrate similar patterns of delayed symptom amplification, cognitive exertion intolerance, orthostatic volatility, sensory sensitivity, treatment sensitivity, and fluctuating functional reserve.

Importantly, Therapeutic Polarity™ does not propose a single universal mechanism underlying all IACCs. Rather, it proposes that multiple upstream pathologies may converge upon shared downstream terrain instability involving impaired mitochondrial reserve, oxidative stress amplification, endothelial dysfunction, neurovascular compensation failure, immune activation, autonomic dysregulation, and narrowed adaptive metabolic windows. This framing is consistent with network medicine models in which distinct initiating insults can converge on shared systems level failure states (Barabási et al., 2011; Loscalzo and Barabási, 2011).

This interpretation may help reconcile longstanding disagreements surrounding disease classification. Distinct triggers such as viral infection, bacterial infection, mold exposure, traumatic injury, autoimmune activation, or environmental stress may each produce overlapping downstream patterns of physiologic destabilization despite differing initiating events. Under such conditions, variability in treatment response becomes expected rather than contradictory.

Recognition of adaptive reserve instability may therefore improve rehabilitation safety, pacing strategies, disability assessment, therapeutic sequencing, cognitive recovery modeling, flare prevention, autonomic stabilization, and individualized treatment planning. These domains are especially relevant because many healthcare systems still assume relatively stable physiologic baselines when designing return to work expectations, exercise based rehabilitation protocols, cognitive recovery timelines, and disability evaluation systems. In patients operating within unstable reserve states, routine physiologic demands may produce disproportionate deterioration.

This framework may also hold implications for aging and neurodegenerative disease research. Iron dysregulation, endothelial dysfunction, oxidative stress accumulation, mitochondrial decline, blood brain barrier dysfunction, and impaired neurovascular coupling are increasingly implicated across Alzheimer’s disease, Parkinson’s disease, vascular cognitive impairment, traumatic brain injury, and related neurodegenerative syndromes (Ward et al., 2014; Sweeney et al., 2018; Iadecola, 2017; Ashraf et al., 2018). The FTL1 study is especially relevant because it demonstrates that iron associated neuronal dysfunction can impair cognition through synaptic and mitochondrial mechanisms, while remaining at least partially modifiable in animal models. Long COVID and ME/CFS may therefore provide important systems level models for understanding how fluctuating adaptive reserve contributes to chronic neurologic dysfunction more broadly.

15. CYNAERA Systems Integration and Adaptive Reserve Modeling

Therapeutic Polarity is intended not solely as a theoretical framework but as part of a broader systems architecture for modeling dynamic physiologic instability in infection associated chronic conditions. Within the CYNAERA ecosystem, this framework integrates with existing work involving flare prediction, environmental destabilization analysis, PEM threshold mapping, neurocognitive variability tracking, and adaptive reserve assessment.

Two CYNAERA papers are especially relevant to this integration: PEM and Remission: A CYNAERA Framework for Understanding Post Exertional Malaise as a Reversible Systems Collapse and Gaming as a Digital Biomarker: Measuring Cognitive Drift, Reaction Time Instability, and Functional Decline in IACCs. The PEM framework establishes the threshold model underlying delayed systems collapse following cumulative physiologic load. Therapeutic Polarity extends this logic by proposing that interventions themselves may function as load events capable of stabilizing or destabilizing the terrain depending upon current reserve state.

The gaming and digital biomarker framework provides a complementary measurement layer. Reaction time drift, endurance decline, sensory disengagement, cognitive variability, reduced multitasking tolerance, prolonged recovery lag, and task abandonment patterns may provide early indicators of adaptive reserve depletion before overt functional collapse becomes clinically apparent. This interpretation aligns with broader digital biomarker literature emphasizing longitudinal behavioral variability as a sensitive marker of neurologic dysfunction and physiologic instability (Insel, 2017; Dagum, 2018; Rutkove et al., 2020).

Within this integrated model, therapeutic response is interpreted dynamically rather than statically. Environmental exposure, infection, sleep disruption, hormonal fluctuation, autonomic stress, sensory overload, inflammatory activation, cognitive demand, and medication changes may each alter reserve state and therefore modify treatment tolerability over time. This systems level perspective aligns with broader precision medicine and systems biology frameworks emphasizing longitudinal physiologic modeling rather than static disease categorization alone (Collins and Varmus, 2015; Ashley, 2016; Barabási et al., 2011).

Potential future integration domains may include:

• SymCas for symptom cascade and flare prediction modeling

• VitalGuard for environmental destabilization overlays

• PEM threshold mapping for exertional reserve analysis

• neurovascular instability modeling

• digital cognitive variability tracking

• adaptive reserve scoring systems

• longitudinal flare prediction analysis

Such integration may support more adaptive clinical trial structures and personalized treatment modeling approaches. Rather than relying solely upon static baseline versus endpoint comparisons, future systems may incorporate physiologic variability tracking, longitudinal reserve monitoring, PEM threshold assessment, cognitive endurance analysis, neurovascular profiling, and environmental destabilization overlays. This framework additionally supports the possibility that many therapeutic failures in Long COVID and ME/CFS may reflect terrain mismatch rather than complete absence of efficacy. Under Therapeutic Polarity, intervention success depends not solely upon mechanism of action, but upon whether the patient possesses sufficient adaptive reserve to tolerate the metabolic, autonomic, vascular, cognitive, or inflammatory demand associated with the therapy. Accordingly, future precision medicine systems may increasingly require dynamic reserve modeling rather than static disease categorization alone.

16. Limitations

Several important limitations should be acknowledged. Therapeutic Polarity™ represents a systems level conceptual framework integrating findings from neurovascular biology, mitochondrial medicine, iron dysregulation research, autonomic physiology, PEM studies, digital biomarker theory, and neuroimmune modeling. Many of the proposed interactions remain incompletely understood and require prospective validation across diverse patient populations.

Long COVID, ME/CFS, and related IACCs remain highly heterogeneous conditions with substantial biologic variability between patients. Not all individuals will demonstrate identical mechanisms, biomarkers, treatment responses, or physiologic trajectories. Ferritin elevations, iron dysregulation, endothelial dysfunction, autonomic instability, neurovascular impairment, mast cell activation, and mitochondrial abnormalities may vary considerably across disease subtypes and illness stages (Komaroff and Lipkin, 2021; Davis et al., 2023; Proal and VanElzakker, 2021).

Additionally, many currently available biomarkers remain indirect measures of complex underlying physiologic processes. Standard laboratory testing may not adequately capture localized tissue level oxidative stress, neurovascular instability, mitochondrial reserve depletion, cerebral perfusion variability, or dynamic fluctuations in adaptive capacity. Further work is needed to identify reliable longitudinal markers capable of monitoring terrain state and therapeutic tolerance more precisely. The relationship between ferritin, FTL1, oxidative stress, mitochondrial dysfunction, and cognitive impairment also remains incompletely established in human IACC populations. Although converging evidence supports biologic plausibility, causality has not been definitively proven. Existing Long COVID ferritin studies are observational and require replication in larger, longitudinal cohorts . Similarly, FTL1 findings in cognition are currently based on animal and cellular models, and translational relevance to human Long COVID, ME/CFS, and broader IACCs requires direct investigation .

Digital biomarker systems and gaming based monitoring strategies also require further validation before widespread clinical implementation. While digital performance variability may offer a promising window into cognitive reserve, these tools must account for confounding variables including sleep, medication effects, pain, mood, sensory overload, visual strain, device differences, baseline gaming experience, and accessibility needs. Importantly, this framework is not intended to discourage treatment or rehabilitation. Rather, it proposes that therapeutic efficacy and tolerability may depend heavily upon sequencing, timing, physiologic reserve, and terrain stability. Future prospective studies will be necessary to determine how Therapeutic Polarity™ may best inform rehabilitation protocols, precision medicine strategies, and adaptive treatment modeling in clinical practice.

17. Conclusion

Long COVID, ME/CFS, and related infection associated chronic conditions may represent disorders of unstable adaptive physiology in which treatment outcome depends not solely upon intervention selection, but upon biologic timing, neurovascular reserve, mitochondrial capacity, iron redox stability, autonomic regulation, endothelial integrity, inflammatory load, and PEM threshold dynamics. Under Therapeutic Polarity™, variability in treatment response becomes interpretable physiology rather than inconsistency alone. Interventions capable of improving cognition, circulation, mitochondrial output, immune regulation, or neuroplasticity under stable conditions may become destabilizing when introduced into terrain states operating near adaptive limit. Conversely, therapies previously associated with worsening may later become beneficial following physiologic stabilization and reserve restoration.

This framework integrates emerging evidence involving ferritin dysregulation, FTL1 mediated cognitive impairment, mitochondrial dysfunction, neurovascular instability, autonomic dysregulation, oxidative stress, cerebral perfusion abnormalities, digital functional drift, and post exertional malaise into a broader systems model of dynamic therapeutic tolerance. Importantly, Therapeutic Polarity™ does not reject conventional therapeutics. Rather, it reframes efficacy as context dependent. The central question may no longer be simply whether a treatment works, but under which physiologic conditions, sequencing states, and adaptive reserve thresholds that treatment remains therapeutic rather than becoming stress.

Future precision medicine approaches in Long COVID, ME/CFS, and broader IACCs may therefore require dynamic reserve assessment, longitudinal monitoring, physiologic stratification, and terrain based sequencing models rather than static intervention algorithms alone. Under this interpretation, chronic illness may not simply reflect damaged physiology, but unstable adaptive physiology operating within narrowed reserve margins.

Frequently Asked Questions (FAQ)

What is Therapeutic Polarity™?

Therapeutic Polarity™ is a CYNAERA systems framework describing how the same intervention may help, harm, or destabilize depending upon the patient’s current physiologic terrain state. Treatment response is interpreted dynamically through factors including mitochondrial reserve, autonomic stability, endothelial integrity, oxidative burden, neurovascular compensation, inflammatory load, and PEM threshold sensitivity.

Does Therapeutic Polarity™ suggest treatments are dangerous?

No. The framework does not classify therapies as inherently beneficial or harmful. Instead, it proposes that treatment outcome may depend heavily upon biologic timing, sequencing, reserve state, and adaptive capacity. Interventions that improve function in one terrain state may become destabilizing in another.

How does this differ from traditional rehabilitation models?

Conventional rehabilitation models often assume relatively stable physiologic baselines and linear adaptation to increasing exertion. Therapeutic Polarity™ proposes that many IACC patients operate within fluctuating adaptive reserve states in which excessive physiologic demand may trigger delayed deterioration rather than conditioning improvement.

What role does post exertional malaise play?

PEM functions as a central organizing feature within the framework. Under Therapeutic Polarity™, interventions themselves may function as physiologic load events capable of contributing to PEM when metabolic, autonomic, neurovascular, or oxidative demand exceeds available adaptive reserve.

Why are ferritin and FTL1 important?

Emerging evidence suggests that ferritin and ferritin light chain 1 (FTL1) may contribute to oxidative stress amplification, mitochondrial dysfunction, synaptic instability, and cognitive impairment. The framework proposes that iron redox dysregulation may represent one contributor to unstable neuro metabolic terrain in Long COVID and ME/CFS.

Does this framework claim all patients share the same mechanism?

No. Long COVID, ME/CFS, and broader IACCs remain highly heterogeneous. Therapeutic Polarity™ proposes that multiple upstream triggers may converge upon overlapping downstream terrain instability involving adaptive reserve depletion, oxidative stress, autonomic dysfunction, neurovascular instability, and impaired recovery physiology.

How does this connect to digital biomarkers?

The framework proposes that reaction time variability, endurance decline, cognitive drift, sensory disengagement, and prolonged recovery patterns may serve as early indicators of terrain destabilization. Gaming and digital performance systems may therefore help detect physiologic instability before overt functional collapse becomes clinically apparent.

Could this framework improve clinical trial design?

Potentially. Therapeutic Polarity™ suggests that inconsistent therapeutic trial outcomes may partially reflect heterogeneous terrain states, differing PEM thresholds, autonomic instability, and reserve variability rather than complete absence of efficacy. More adaptive and longitudinal monitoring strategies may improve subgroup stratification and reduce treatment induced destabilization.

Is Therapeutic Polarity™ limited to Long COVID and ME/CFS?

No. The framework may have relevance across broader neuroimmune and chronic illness populations involving fluctuating adaptive reserve, including dysautonomia, mast cell disorders, chronic Lyme disease, post sepsis syndromes, traumatic brain injury recovery, and certain neurodegenerative conditions.

Is this framework clinically validated?

Not yet. Therapeutic Polarity™ is currently presented as a systems level conceptual framework integrating findings across neurovascular biology, mitochondrial medicine, iron dysregulation research, autonomic physiology, PEM science, and digital biomarker theory. Prospective validation studies are needed.

CYNAERA Framework Papers and Core Research Libraries

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library,  ME/CFS Library, Lyme Library,  Autoimmune Library and CRISPR Remission Library are also in depth resources.

• Gaming As A Digital Biomarker

• Primary Chronic Trigger (PCT)™ 

• CYNAERA Remission Standard™

• The Body First Trial Protocol™

• Preliminary Findings from The Eve Research Project

• Biological Adaptive Reduction State™ (BARS™)

• Aligned Intelligence Method (AIM™)

• The Hidden Public Health Cost of AI Data Centers

• ​Composite Diagnostic Fingerprint for Long COVID

• SymCas™: Symptom Flare Prediction in IACCs

• VitalGuard™ Environmental Flare Risk Engine

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.

Licensing and Integration

CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.

About the Author 

Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.

Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey,  Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.

She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research  with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.

Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.

References

1. Appelman, B., Charlton, B.T., Goulding, R.P., et al. (2024) ‘Muscle abnormalities worsen after post exertional malaise in Long COVID’, Nature Communications, 15, pp. 1–15.

2. Ashley, E.A. (2016) ‘Towards precision medicine’, Nature Reviews Genetics, 17(9), pp. 507–522.

3. Ashraf, A., Clark, M. and So, P.W. (2018) ‘The aging of iron man’, Frontiers in Aging Neuroscience, 10, pp. 65–79.

4. Barabási, A.L., Gulbahce, N. and Loscalzo, J. (2011) ‘Network medicine: a network based approach to human disease’, Nature Reviews Genetics, 12(1), pp. 56–68.

5. Biswal, B., Kunwar, P., Natelson, B.H. (2011) ‘Cerebral blood flow is reduced in chronic fatigue syndrome’, BMC Neurology, 11, pp. 1–9.

6. Brosschot, J.F., Verkuil, B. and Thayer, J.F. (2018) ‘Generalized unsafety theory of stress’, Neuroscience & Biobehavioral Reviews, 92, pp. 218–226.

7. Butterfield, D.A. and Halliwell, B. (2019) ‘Oxidative stress and neurodegeneration’, Nature Reviews Neuroscience, 20(3), pp. 148–160.

8. Cairo, G., Bernuzzi, F. and Recalcati, S. (2021) ‘A precious metal: iron, an essential nutrient for all cells’, Genes & Nutrition, 16(1), pp. 1–15.

9. Calabrese, E.J. (2008) ‘Hormesis and medicine’, British Journal of Clinical Pharmacology, 66(5), pp. 594–617.

10. Charfeddine, S., Ibn Hadj Amor, H., Jdidi, J., et al. (2021) ‘Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction?’, Insights into Imaging, 12(1), pp. 1–10.

11. Cockshell, S.J. and Mathias, J.L. (2010) ‘Cognitive functioning in chronic fatigue syndrome’, Psychological Medicine, 40(8), pp. 1253–1267.

12. Collins, F.S. and Varmus, H. (2015) ‘A new initiative on precision medicine’, New England Journal of Medicine, 372(9), pp. 793–795.

13. Covassin, T., Elbin, R.J. and Nakayama, Y. (2012) ‘Tracking neurocognitive performance following concussion’, Physical Medicine and Rehabilitation Clinics, 22(4), pp. 683–700.

14. Dagum, P. (2018) ‘Digital biomarkers of cognitive function’, NPJ Digital Medicine, 1(10), pp. 1–3.

15. Davenport, T.E., Stevens, S.R., VanNess, J.M., et al. (2019) ‘Conceptual model for physical therapist management of chronic fatigue syndrome’, Physical Therapy, 90(4), pp. 602–614.

16. Davis, H.E., McCorkell, L., Vogel, J.M. and Topol, E.J. (2023) ‘Long COVID: major findings, mechanisms and recommendations’, Nature Reviews Microbiology, 21(3), pp. 133–146.

17. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., et al. (2012) ‘Ferroptosis: an iron dependent form of nonapoptotic cell death’, Cell, 149(5), pp. 1060–1072.

18. Dong, X.X., Wang, Y. and Qin, Z.H. (2009) ‘Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases’, Acta Pharmacologica Sinica, 30(4), pp. 379–387.

19. Erickson, M.A. and Banks, W.A. (2018) ‘Age associated changes in the immune system and blood brain barrier functions’, International Journal of Molecular Sciences, 20(7), pp. 1632–1648.

20. Giza, C.C. and Hovda, D.A. (2014) ‘The new neurometabolic cascade of concussion’, Neurosurgery, 75(4), pp. S24–S33.

21. Gómez Pastor, R., Rothenberg, M.E. and Gómez, H. (2020) ‘Hyperferritinemia in critically ill COVID 19 patients’, Current Opinion in Critical Care, 26(6), pp. 633–639.

22. Iadecola, C. (2017) ‘The neurovascular unit coming of age’, Neuron, 96(1), pp. 17–42.

23. Insel, T.R. (2017) ‘Digital phenotyping: technology for a new science of behavior’, JAMA, 318(13), pp. 1215–1216.

24. Institute of Medicine (2015) Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press.

25. Jason, L.A., Evans, M., Porter, N., et al. (2011) ‘The development of a revised Canadian myalgic encephalomyelitis chronic fatigue syndrome case definition’, American Journal of Biochemistry and Biotechnology, 6(2), pp. 120–135.

26. Kell, D.B. (2009) ‘Iron behaving badly’, BMC Medical Genomics, 2(2), pp. 1–79.

27. Kell, D.B. and Pretorius, E. (2014) ‘Serum ferritin is an important inflammatory disease marker’, Metallomics, 6(4), pp. 748–773.

28. Kell, D.B., Laubscher, G.J. and Pretorius, E. (2022) ‘A central role for amyloid fibrin microclots in Long COVID’, Biochemical Journal, 479(4), pp. 537–559.

29. Komaroff, A.L. and Lipkin, W.I. (2021) ‘Insights from myalgic encephalomyelitis/chronic fatigue syndrome’, Nature Reviews Microbiology, 19(10), pp. 635–649.

30. Lim, Y.Y., Snyder, P.J., Pietrzak, R.H., et al. (2019) ‘Sensitivity of cognitive measures in preclinical Alzheimer disease’, Neurology, 92(11), pp. 1–12.

31. Loscalzo, J. and Barabási, A.L. (2011) ‘Systems biology and the future of medicine’, Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 3(6), pp. 619–627.

32. Magistretti, P.J. and Allaman, I. (2018) ‘Lactate in the brain’, Nature Reviews Neuroscience, 19(4), pp. 235–249.

33. McEwen, B.S. (1998) ‘Protective and damaging effects of stress mediators’, New England Journal of Medicine, 338(3), pp. 171–179.

34. Missailidis, D., Sanislav, O., Allan, C.Y., et al. (2021) ‘An isolated complex V inefficiency in ME/CFS lymphoblasts’, International Journal of Molecular Sciences, 22(4), pp. 1–16.

35. Naviaux, R.K. (2019) ‘Incomplete healing as a cause of aging’, Mitochondrion, 46, pp. 278–297.

36. Nijs, J., Meeus, M., Van Oosterwijck, J., et al. (2013) ‘In the mind or in the brain?’, Clinical and Experimental Rheumatology, 30(6), pp. 141–147.

37. Pellerin, L. and Magistretti, P.J. (1994) ‘Glutamate uptake into astrocytes stimulates aerobic glycolysis’, Proceedings of the National Academy of Sciences, 91(22), pp. 10625–10629.

38. Pretorius, E., Vlok, M., Venter, C., et al. (2022) ‘Persistent clotting protein pathology in Long COVID’, Cardiovascular Diabetology, 21(1), pp. 1–18.

39. Proal, A.D. and VanElzakker, M.B. (2021) ‘Long COVID or post acute sequelae of COVID 19’, Frontiers in Microbiology, 12, pp. 1–15.

40. Rutkove, S.B., Narayanaswami, P. and Berisha, V. (2020) ‘Digital biomarkers in neurology’, Muscle & Nerve, 61(3), pp. 293–304.

41. Shan, Z.Y., Kwiatek, R., Burnet, R., et al. (2020) ‘Progressive brain changes in chronic fatigue syndrome’, Journal of Nuclear Medicine, 61(12), pp. 1–9.

42. Sokolakis, I., Koukoulis, G., Teohidis, I., et al. (2023) ‘Endothelial dysfunction in Long COVID’, Vascular Medicine, 28(2), pp. 102–112.

43. Sterling, P. and Eyer, J. (1988) ‘Allostasis: a new paradigm to explain arousal pathology’, in Fisher, S. and Reason, J. (eds.) Handbook of Life Stress, Cognition and Health. New York: Wiley, pp. 629–649.

44. Stockwell, B.R., Friedmann Angeli, J.P., Bayir, H., et al. (2017) ‘Ferroptosis in disease’, Cell, 171(2), pp. 273–285.

45. Sweeney, M.D., Kisler, K., Montagne, A., et al. (2018) ‘The role of brain vasculature in neurodegenerative disorders’, Nature Neuroscience, 21(10), pp. 1318–1331.

46. Systrom, D.M., McNamara, R., Grady, C., et al. (2022) ‘Exercise intolerance in ME/CFS’, Journal of the American College of Cardiology, 79(20), pp. 1–13.

47. Tanaka, M., Ishii, A. and Watanabe, Y. (2002) ‘Neural mechanisms underlying chronic fatigue’, Reviews in the Neurosciences, 16(2), pp. 251–262.

48. Topol, E.J. (2014) The Patient Will See You Now. New York: Basic Books.

49. Van Campen, C.L.M.C., Rowe, P.C. and Visser, F.C. (2020) ‘Cerebral blood flow reduction during tilt testing in ME/CFS’, Clinical Neurophysiology Practice, 5, pp. 50–58.

50. Vargas Vargas, M. and Cortés Roa, M.C. (2020) ‘Ferritin levels and COVID 19’, Revista Panamericana de Salud Pública, 44, pp. 1–6.

51. Ward, R.J., Zucca, F.A., Duyn, J.H., et al. (2014) ‘The role of iron in brain ageing and neurodegenerative disorders’, Lancet Neurology, 13(10), pp. 1045–1060.

52. Wirth, K. and Scheibenbogen, C. (2021) ‘A unifying hypothesis of ME/CFS’, Frontiers in Immunology, 11, pp. 1–14.